Genomics & Genetics Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genomics & Genetics Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease
Reports from R. Lane and co-researchers add new data to research in Alzheimer disease
July 4th, 2008
According to a study from the United States, " To evaluate the synergistic effects of the apolipoprotein E (APOE) epsilon 4 and butyrylcholinesterase K-variant (BCHE-K) alleles on progression to Alzheimer's disease (AD) in individuals with mild cognitive impairment (MCI). This was a post-hoc exploratory analysis from a 3-4-year, randomized, placebo-controlled study of rivastigmine in participants with MCI (InDDEx study)." "Participants who consented to genetic testing were included in the current analyses. The incidence of progression to AD, cognitive decline and changes in MRI brain volumes were investigated in participants from the placebo arm of the InDDEx study. ...
Source: Genomics & Genetics Weekly (2008-07-04)
|
